Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31142436 | 0.77 | — | — | |
| SCHEMBL8199262 | 0.73 | — | — | |
| Mellitic Acid SCHEMBL23507 | 0.58 | CYP1A2 (0.50) | FABP3FABP4 | |
| Mellitic Acid SCHEMBL22971 | 0.58 | CYP1A2 (0.50) | FABP3FABP4 | |
| Mellitic Acid SCHEMBL28360695 | 0.55 | CYP1A2 (0.47) | FABP3FABP4 | |
| Mellitic Acid SCHEMBL28353323 | 0.55 | CYP1A2 (0.47) | FABP3FABP4 | |
| Mellitic Acid SCHEMBL9644343 | 0.55 | CYP1A2 (0.47) | FABP3FABP4 | |
| Mellitic Acid SCHEMBL28758936 | 0.55 | CYP1A2 (0.47) | FABP3FABP4 | |
| Mellitic Acid SCHEMBL29638026 | 0.55 | CYP1A2 (0.47) | FABP3FABP4 | |
| Mellitic Acid SCHEMBL9407783 | 0.55 | CYP1A2 (0.47) | FABP3FABP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250255889-A1 | METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | THE BROAD INSTITUTE, INC. (US) | 2025-08-14 | — | — | US | claimed |
| CN-115096928-B | Method for detecting monovalent copper based on EPR technology | 天津医科大学 | 2025-05-30 | — | — | CN | claimed |
| WO-2024064766-A2 | METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | THE BROAD INSTITUTE, INC. (US) | 2024-03-28 | — | — | WO | claimed |
| CN-115096928-A | Method for detecting monovalent copper based on EPR technology | 天津医科大学 | 2022-09-23 | — | — | CN | claimed |
| CN-111007158-B | Method for separating and measuring related substances in preparation process of crizotinib | 上海柏狮生物科技有限公司 | 2022-08-12 | — | — | CN | claimed |
| US-20250255889-A1 | METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | THE BROAD INSTITUTE, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| CN-120153452-A | Slurry composition for dielectric layer, and capacitor | 日本瑞翁株式会社 | 2025-06-13 | — | — | CN | disclosed |
| CN-115096928-B | Method for detecting monovalent copper based on EPR technology | 天津医科大学 | 2025-05-30 | — | — | CN | disclosed |
| CN-118973962-A | Spherical calcium titanate powder and resin composition using same | 电化株式会社 | 2024-11-15 | — | — | CN | disclosed |
| US-20240239988-A1 | SEMICONDUCTOR ELEMENT ENCAPSULATION RESIN COMPOSITION AND SEMICONDUCTOR DEVICE HAVING CURED PRODUCT THEREOF | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2024095663-A1 | SLURRY COMPOSITION FOR DIELECTRIC LAYER, DIELECTRIC LAYER, AND CAPACITOR | 日本ゼオン株式会社 | 2024-05-10 | — | — | WO | disclosed |
| WO-2024064766-A2 | METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | THE BROAD INSTITUTE, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| CN-218092573-U | Multifunctional rope puller free of punching | 陈晓鹏 | 2022-12-20 | — | — | CN | disclosed |
| CN-115096928-A | Method for detecting monovalent copper based on EPR technology | 天津医科大学 | 2022-09-23 | — | — | CN | disclosed |
| CN-217461802-U | Door stopper convenient to location installation | 浙江美拓智能科技有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-111007158-B | Method for separating and measuring related substances in preparation process of crizotinib | 上海柏狮生物科技有限公司 | 2022-08-12 | — | — | CN | disclosed |
| CN-217001336-U | Adjustable door stopper | 陈晓鹏 | 2022-07-19 | — | — | CN | disclosed |
| EP-4008822-A1 | SILK FIBER-CONTAINING NONWOVEN FABRIC, WOUND DRESSING, IPS CELL SCAFFOLD MATERIAL, NONWOVEN FABRIC FOR BLOOD COMPATIBLE MATERIAL, BLOOD COMPATIBLE MATERIAL, METHOD FOR PRODUCING SILK FIBER-CONTAINING NONWOVEN FABRIC, METHOD FOR PRODUCING WOUND DRESSING, METHOD FOR PRODUCING IPS CELL SCAFFOLD MATERIAL, METHOD FOR PRODUCING NONWOVEN FABRIC FOR BLOOD COMPATIBLE MATERIAL, AND METHOD FOR PRODUCING BLOOD COMPATIBLE MATERIAL | Central Glass Co., Ltd. (JP) | 2022-06-08 | — | — | EP | disclosed |
| EP-3188266-B1 | A METHOD FOR MANUFACTURING A STATOR FOR A PIEZOELECTRIC OSCILLATORY WAVE MOTOR | CANON KK (JP) | 2022-04-06 | — | — | EP | disclosed |
| US-11272080-B2 | Vibration device for dust removal and imaging device | CANON KABUSHIKI KAISHA (JP) | 2022-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250255889-A1 | METHODS FOR TREATMENT SELECTION FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) | BCL6B, BCL9, BCL9L | FABP3 816/4885FABP4 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.